Introduction to Class Action for Capricor Investors
The Gross Law Firm has recently reached out to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR), encouraging them to participate in a class action lawsuit. If you have purchased shares of Capricor during the specified period, your involvement could be vital in seeking justice and recovery of losses incurred.
Understanding the Class Period
The designated class period for this action spans from October 9, 2024, to July 10, 2025. Shareholders who acquired their shares during this timeframe should consider registering with the firm for potential lead plaintiff opportunities. Being a lead plaintiff can amplify your role in the case, although it is not mandatory to be involved in the recovery process.
Allegations Against Capricor
The allegations center on Capricor's communications regarding their lead cell therapy candidate, deramiocel, which is aimed at addressing cardiomyopathy—a severe condition linked with Duchenne muscular dystrophy (DMD). In a concerning turn, it was claimed that Capricor misled investors about its ability to secure a Biologics License Application from the FDA. These statements were made despite concerning undisclosed details from their Phase 2 HOPE-2 trial that indicated potential safety and efficacy issues.
Significant Decline in Share Price
On July 11, 2025, Capricor announced it had received a Complete Response Letter (CRL) from the FDA, which effectively denied their application due to insufficient evidence of its effectiveness. This revelation led to a significant decline in Capricor's stock price, dropping from $11.40 per share to $7.64 within a single day. This dramatic fall is a stark reminder of the volatility and risk associated with investment in biopharmaceutical companies.
Understanding the Deadlines
Investors interested in participating should be aware of critical deadlines, particularly the September 15, 2025, cut-off for seeking lead plaintiff status. Prompt registration is essential to ensure your voice is heard within this case, and investors are encouraged not to delay in submitting their information. Participation comes with no financial obligation, allowing shareholders to engage without excessive risk.
Next Steps for Interested Shareholders
Once you express your interest as a shareholder who purchased shares of CAPR during the specified timeframe, you will gain access to a portfolio monitoring system. This tool will provide regular updates and keep you informed through the lifecycle of the case. Such measures are designed to ensure transparent communication and a clear understanding of your position in the class action.
Why Choose the Gross Law Firm?
The Gross Law Firm stands out as a well-established entity committed to defending investor rights. Their mission emphasizes protecting stakeholders who have faced losses due to deceptive practices, including fraud and misleading statements. They advocate for ethical business conduct and strive to recover losses for investors impacted by harmful corporate practices. Engagement with a firm of their caliber can enhance the chances of a favorable outcome.
Contact Information for Capricor Shareholders
For shareholders ready to register their interest or learn more about the class action process, you can contact The Gross Law Firm directly. Preparation and proactive engagement are key components for those looking to see justice served in the case against Capricor Therapeutics.
Frequently Asked Questions
1. What is the class period for the Capricor action?
The class period runs from October 9, 2024, to July 10, 2025, during which shareholders can file for participation.
2. How do I register for the class action?
Interested shareholders should contact The Gross Law Firm to submit their registration details as soon as possible.
3. What are the allegations against Capricor Therapeutics?
The company is accused of misleading investors about its drug candidate, deramiocel, and failing to disclose critical safety and efficacy data.
4. What is a Complete Response Letter from the FDA?
A Complete Response Letter indicates that the FDA did not approve a drug application due to various deficiencies that must be addressed before resubmission.
5. Why should I consider joining this class action?
Joining can help you recover losses while also holding companies accountable for misleading investors, thus improving transparency in the market.
